Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III
CONCLUSIONS: This integrated analysis supports the findings of PRASTRO-III. Prasugrel is a promising treatment that results in a numerical reduction in the composite incidence of ischemic stroke, MI, and death from other vascular causes in patients with ischemic stroke who are at a high risk of stroke recurrence. No major safety issues were observed for prasugrel.PMID:37011599 | DOI:10.1159/000529149
Source: Atherosclerosis - April 3, 2023 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Toshiaki Shirai Atsushi Takita Takeshi Kuroda Kazumi Kimura Source Type: research

Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
CONCLUSIONS: Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. This could be a novel strategy for cardioembolic stroke prevention potentially by affecting cardiac remodelling, in contrast to secondary anticoagulant therapy. PMID: 25798683 [PubMed - as supplied by publisher]
Source: Neurological Research - March 24, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Antiplatelet therapy after stroke: should it differ in the acute and chronic phase after stroke
Purpose of review Reviewing existing evidence regarding well tolerated and effective antiplatelet treatment in patients with acute or chronic, noncardioembolic ischemic stroke and transient ischemic attack (TIA). Recent findings For patients with high-risk stroke or TIA, for instance, minor stroke or high-risk TIA, or stroke of atherosclerotic origin with evidence suggesting risk of artery-to-artery embolism or with high-grade, symptomatic arterial stenosis, early initiated, short-term dual antiplatelet (e.g. aspirin and clopidogrel) is effective in reducing the risk of recurrent stroke and other vascular events which...
Source: Current Opinion in Neurology - December 20, 2017 Category: Neurology Tags: CEREBROVASCULAR DISEASE: Edited by Hugh S. Markus Source Type: research

Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients
AbstractAntiplatelet agents may increase the risk of infections via suppressing platelet-mediated immune response. Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission. A retrospective cohort study was conducted of acute ischemic stroke patients who were admitted to our hospital from 2015 to 2018. Included patients received uninterrupted clopidogrel or aspirin therapy and did not take other antiplatelet agents throughout their stay. The interest outcome was development of pneumonia after stroke. Conditional logistic regression model after ...
Source: Journal of Thrombosis and Thrombolysis - October 9, 2020 Category: Hematology Source Type: research

The frequency of CYP2C19 loss-of-function variants in patients with non-cardioembolic ischemic stroke or transient ischemic attack in the Dutch population
Discussion and conclusion: About a quarter of patients with non-cardioembolic ischemic stroke or TIA in the Dutch population carry a CYP2C19 LOF variant. This is lower than estimates found in studies with Asian populations, but similar to estimates found among Caucasian patients in other parts of the world.
Source: Cerebrovascular Diseases - March 22, 2023 Category: Neurology Source Type: research

Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
CONCLUSIONS: In this prespecified analysis of the CHANCE-2 trial, the efficacy and safety of ticagrelor-aspirin versus clopidogrel-aspirin in preventing new stroke were consistent in patients with different causes. The influence of stroke cause on benefit of gene-guided antiplatelet therapy should be explored by further trials.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04078737.PMID:37548009 | DOI:10.1161/STROKEAHA.122.042233
Source: Atherosclerosis - August 7, 2023 Category: Cardiology Authors: Xuewei Xie Jing Jing Xia Meng S Claiborne Johnston Philip M Bath Zixiao Li Xingquan Zhao Liping Liu Yilong Wang Qin Xu Anxin Wang Yong Jiang Hao Li Yongjun Wang CHANCE-2 Investigators Source Type: research

Interest of Antiplatelet Drug Testing after an Acute Ischemic Stroke
Background: Stroke occurrence despite chronic antiplatelet drug (APD) treatment is frequent. We aimed at evaluating the relevance of platelet aggregation testing in the identification of stroke etiology in this context. Methods: Patients admitted for a suspected acute ischemic stroke, while under APD (aspirin and/or clopidogrel), were prospectively included. The efficacy of the APD was evaluated using a Multiplate™ assay. Resistance was confirmed using light transmission aggregometry. A standardized diagnostic work-up was performed to identify stroke mechanism according to the TOAST and the ASCO classifications. We evalu...
Source: European Neurology - September 14, 2015 Category: Neurology Source Type: research

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis.
CONCLUSIONS: -Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events compared with non-carriers among patients with ischemic stroke or TIA treated with clopidogrel. PMID: 27806998 [PubMed - as supplied by publisher]
Source: Circulation - November 1, 2016 Category: Cardiology Authors: Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang QW, Li X, Huang L, Johnston SC, Zhao X, Liu L, Zhang Q, Wang G, Wang Y, Wang Y Tags: Circulation Source Type: research

Acute Ischemic Stroke as a Presenting Feature of Multiple Myeloma (P3.279)
Conclusions:Stroke is a leading and preventable cause of disability in the US adult population. The majority of strokes are due to atherosclerotic vascular or cardioembolic disease. Understanding the diagnostic work up of stroke and recognizing rare etiologies like MM is important for stroke prevention. This brings to light the importance of recognizing stroke as an initial presenting feature of multiple myeloma and of multiple myeloma as an important treatable etiology of stroke.Disclosure: Dr. Chung has nothing to disclose. Dr. Ramamoorthy has nothing to disclose. Dr. Kar has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chung, S., Ramamoorthy, R., Kar, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research

Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials
Conclusions: Among patients who presented with ischemic stroke/TIA, short-course clopidog rel plus aspirin immediately following the index event appears to be more effective than and as safe as monotherapy for secondary stroke prevention.
Source: Journal of Thrombosis and Thrombolysis - December 3, 2018 Category: Hematology Source Type: research

Stress hyperglycemia may have higher risk of stroke recurrence than previously diagnosed diabetes mellitus
Aging (Albany NY). 2021 Mar 22;13. doi: 10.18632/aging.202797. Online ahead of print.ABSTRACTWe aim to evaluate the risk of stroke recurrence among non-diabetes mellitus (non-DM), previously diagnosed diabetes mellitus (PDDM), newly diagnosed diabetes mellitus-related hyperglycemia (NDDM-RH) and stress hyperglycemia after minor stroke or TIA. Totally, 3026 patients with baseline fasting glucose and glycated albumin from the CHANCE trial (Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events) were included. Patients were classified as non-DM, PDDM, NDDM-RH and stress hyperglycemia according to the...
Source: Aging - March 22, 2021 Category: Biomedical Science Authors: Yuzhou Guo Guangyao Wang Jing Jing Anxin Wang Xiaoli Zhang Xia Meng Xingquan Zhao Liping Liu Hao Li David Wang Yongjun Wang Yilong Wang Source Type: research

Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
ConclusionsThis real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

ASA failure: Does the combination ASA/clopidogrel confer better long-term vascular protection?
Conclusions: In patients with a recent lacunar stroke while taking ASA, the addition of clopidogrel did not result in reduction of vascular events vs continuing ASA only. Classification of evidence: This study provides Class I evidence that for patients with recent lacunar stroke while taking ASA, adding clopidogrel as compared to continuing ASA alone does not reduce the risk of recurrent stroke.
Source: Neurology - February 3, 2014 Category: Neurology Authors: Cote, R., Zhang, Y., Hart, R. G., McClure, L. A., Anderson, D. C., Talbert, R. L., Benavente, O. R. Tags: Stroke prevention, Infarction ARTICLE Source Type: research

Recurrent Stroke was Associated with Poor Quality of Life in Patients with Transient Ischemic Attack or Minor Stroke: Finding from the CHANCE Trial.
CONCLUSIONS: Stroke recurrence was associated with poor HRQOL in patients with TIA or minor strokes. Interventions focusing on controlling risk factors and prevention of worsening of neurological function may prevent poor HRQOL in these patients. PMID: 25307297 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - October 13, 2014 Category: Neuroscience Authors: Wang YL, Pan YS, Zhao XQ, Wang D, Johnston SC, Liu LP, Meng X, Wang AX, Wang CX, Wang YJ, The CHANCE investigators Tags: CNS Neurosci Ther Source Type: research